Stocksigma LogoStocksigma Logo

Kilitch Drugs Issues EGM Corrigendum on Subsidiary Debt Conversion Share Allotment

Kilitch Drugs (India) issued a corrigendum on 12th Nov'26 for its EGM scheduled on 16th Nov'26, rectifying a typographical error regarding its material

Kilitch Drugs Issues EGM Corrigendum on Subsidiary Debt Conversion Share Allotment

Kilitch Drugs India Ltd 路 Extra Ordinary General Meeting 路 13 Nov 2026, 12:54 am

Kilitch Drugs Issues EGM Corrigendum on Subsidiary Debt Conversion Share Allotment Kilitch Drugs (India) issued a corrigendum on 12th Nov'26 for its EGM scheduled on 16th Nov'26, rectifying a typographical error regarding its material subsidiary, Kilitch Estro Biotech PLC (KEB). Pursuant to outstanding debt conversion, the company will be allotted 1,66,471 additional equity shares in KEB (corrected from 1,66,472), raising its stake from 67% to 89.17%. The entire shareholding will be sold to HarmeeCare Pharmaceuticals for a total consideration of USD 12.855 mn. All other terms of the EGM notice dated 22nd Oct'26 remain unchanged.

Original exchange filing (PDF)

More announcements from Kilitch Drugs India Ltd

All Kilitch Drugs India Ltd announcements